These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 6414221)

  • 21. [Characterization of urokinase type plasminogen activator modified by phenylglyoxal].
    Mukhametova LI; Aĭsina RB; Lomakina GIu; Varfolomeev SD
    Bioorg Khim; 2002; 28(4):308-14. PubMed ID: 12197387
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species.
    Gurewich V; Pannell R; Louie S; Kelley P; Suddith RL; Greenlee R
    J Clin Invest; 1984 Jun; 73(6):1731-9. PubMed ID: 6725557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Demonstration of urokinase-related fibrinolytic activity in human plasma.
    Wijngaards G; Kluft C; Groeneveld E
    Br J Haematol; 1982 May; 51(1):165-9. PubMed ID: 7041952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Fibrinolytic activity of acyl-urokinase].
    Stürzebecher J; Kroneck I; Klöcking HP
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(1-2):137-43. PubMed ID: 2427394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of a recombinant chimeric plasminogen activator composed of Gly-Pro-Arg-Pro tetrapeptide and truncated urokinase-type plasminogen activator expressed in Escherichia coli.
    Hua ZC; Chen XC; Dong C; Zhu DX
    Biochem Biophys Res Commun; 1996 May; 222(2):576-83. PubMed ID: 8670247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma tissue-type plasminogen activator increases fibrinolytic activity of exogenous urokinase-type plasminogen activator.
    Shenkman B; Livnat T; Budnik I; Tamarin I; Einav Y; Martinowitz U
    Blood Coagul Fibrinolysis; 2012 Dec; 23(8):729-33. PubMed ID: 22918041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Methods of urokinase administration based on its pharmacokinetics--pharmacokinetic approach].
    Matsuo O; Kosugi T; Mihara H
    Nihon Rinsho; 1979 Sep; 37(9):3357-61. PubMed ID: 522275
    [No Abstract]   [Full Text] [Related]  

  • 28. Encapsulation of human urokinase in rabbit erythrocytes and its disposition in the circulation system in rabbits.
    Ito Y; Ogiso T; Iwaki M; Atago H
    J Pharmacobiodyn; 1987 Oct; 10(10):550-6. PubMed ID: 3440917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic fibrinolytic activity and inhibitor levels during treatment of deep vein thrombosis with urokinase and streptokinase.
    Theiss W; Asbeck F; Kriessmann A; Trübestein G; Knoch K; de Swart CA; Marbert GA; van de Loo JC
    Thromb Haemost; 1983 Oct; 50(3):664-8. PubMed ID: 6196852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sustained fibrinolytic activity in the euglobulin fraction induced by concomitant administration of urokinase and dextran sulphate.
    Matsuo O; Kawaguchi T; Kosugi T; Mihara H
    Thromb Res; 1978 Dec; 13(6):1125-30. PubMed ID: 749265
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of serum urokinase on urine fibrinolytic activity.
    Hong SY; Pyo SJ; Lee HB
    Nephron; 1990; 55(3):287-91. PubMed ID: 2370929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical and histochemical investigations on in vivo thrombolysis with urokinase in rabbits.
    Hisano S; Sueishi K; Ishii Y; Tanaka K
    Thromb Haemost; 1979 Jun; 41(4):796-803. PubMed ID: 483251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of heparin and a low molecular weight heparinoid on specific endogenous and exogenous fibrinolytic factors during rest and exercise.
    de Boer A; Kluft C; Dooijewaard G; Kasper FJ; Kroon JM; Breimer DD; Stiekema JC; Cohen AF
    Thromb Haemost; 1992 Nov; 68(5):550-5. PubMed ID: 1280862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of furosemide on plasma fibrinolytic activity and urokinase excretion.
    Chohan IS; Singh I; Vermylen J; Verstraete M
    Exp Hematol; 1977 Mar; 5(2):153-7. PubMed ID: 844519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Studies on the activation mechanism of fibrinolytic enzyme system in plasma by human pancreatic elastase.
    Toki N; Takasugi S; Ishizu K; Sato H; Sumi H
    Thromb Haemost; 1982 Feb; 47(1):8-13. PubMed ID: 6176043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of a specific anti-human urokinase antibody: development of a sensitive competition radioimmunoassay for urokinase antigen.
    Huber K; Kirchheimer J; Binder BR
    J Lab Clin Med; 1984 May; 103(5):684-94. PubMed ID: 6715950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of fibrinolytic capacity in plasma during thrombolytic therapy with single (scu-PA) or two-chain urokinase type plasminogen activator (tcu-PA) by a combined assay system for urokinase type plasminogen activator antigen and function.
    Wojta J; Binder BR; Huber K; Hoover RL
    Thromb Haemost; 1989 Apr; 61(2):289-93. PubMed ID: 2501899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy].
    Goto S; Handa S; Abe S; Takahashi E; Kawai Y; Watanabe K; Yoshikawa T; Hori S; Ikeda Y
    J Cardiol; 1993; 23(4):335-41. PubMed ID: 8064582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
    Gurewich V; Pannell R
    Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Measurement of human urokinase activity in plasma by using mono-specific antibody-conjugated paper disk.
    Ogiso T; Ito Y; Iwaki M; Atago H
    J Biochem; 1987 Mar; 101(3):671-7. PubMed ID: 2439494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.